Switch theme
Sign up to access all valuation multiples
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
1996
327
LTM Revenue $0.6M
LTM EBITDA -$296M
$1.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Xenon Pharmaceuticals has a last 12-month revenue of $0.6M and a last 12-month EBITDA of -$296M.
In the most recent fiscal year, Xenon Pharmaceuticals achieved revenue of n/a and an EBITDA of -$277M.
Xenon Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Xenon Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$211M | -$277M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$125M | -$182M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Xenon Pharmaceuticals's stock price is $33.
Xenon Pharmaceuticals has current market cap of $2.6B, and EV of $1.9B.
See Xenon Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.9B | $2.6B | XXX | XXX | XXX | XXX | $-3.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Xenon Pharmaceuticals has market cap of $2.6B and EV of $1.9B.
Xenon Pharmaceuticals's trades at 3042.1x LTM EV/Revenue multiple, and -6.6x LTM EBITDA.
Analysts estimate Xenon Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Xenon Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.9B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -7.0x | XXX | XXX | XXX |
| P/E | -10.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -10.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpXenon Pharmaceuticals's NTM/LTM revenue growth is 1452%
Xenon Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.9M for the same period.
Over next 12 months, Xenon Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Xenon Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Xenon Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 31% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Xenon Pharmaceuticals acquired XXX companies to date.
Last acquisition by Xenon Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Xenon Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Xenon Pharmaceuticals founded? | Xenon Pharmaceuticals was founded in 1996. |
| Where is Xenon Pharmaceuticals headquartered? | Xenon Pharmaceuticals is headquartered in United States of America. |
| How many employees does Xenon Pharmaceuticals have? | As of today, Xenon Pharmaceuticals has 327 employees. |
| Who is the CEO of Xenon Pharmaceuticals? | Xenon Pharmaceuticals's CEO is Mr. Ian C. Mortimer. |
| Is Xenon Pharmaceuticals publicy listed? | Yes, Xenon Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Xenon Pharmaceuticals? | Xenon Pharmaceuticals trades under XENE ticker. |
| When did Xenon Pharmaceuticals go public? | Xenon Pharmaceuticals went public in 2014. |
| Who are competitors of Xenon Pharmaceuticals? | Similar companies to Xenon Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Xenon Pharmaceuticals? | Xenon Pharmaceuticals's current market cap is $2.6B |
| What is the current revenue of Xenon Pharmaceuticals? | Xenon Pharmaceuticals's last 12-month revenue is $0.6M. |
| What is the current EBITDA of Xenon Pharmaceuticals? | Xenon Pharmaceuticals's last 12-month EBITDA is -$296M. |
| What is the current EV/Revenue multiple of Xenon Pharmaceuticals? | Current revenue multiple of Xenon Pharmaceuticals is 3042.1x. |
| What is the current EV/EBITDA multiple of Xenon Pharmaceuticals? | Current EBITDA multiple of Xenon Pharmaceuticals is -6.6x. |
| Is Xenon Pharmaceuticals profitable? | Yes, Xenon Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
